Atherosclerosis and Cerebral Ischemic Attacks: Intakes of Cerebrography With Xenon133 Inhaled and Platelet Tests in the Diagnosis,Clinical and Therapeutic Monitoring;The Preventive Role of Dipyridamole
Restricted accessResearch articleFirst published online November, 1984
Atherosclerosis and Cerebral Ischemic Attacks: Intakes of Cerebrography With Xenon133 Inhaled and Platelet Tests in the Diagnosis,Clinical and Therapeutic Monitoring;The Preventive Role of Dipyridamole
A study of patients to develop the significance of the role of the blood plate lets in the recurrence of transient cerebral ischemic attacks in patients with cerebral atheromatous, develop the effectiveness of dipyridamole in the prophy lactic therapeutic regimen. In the group treated with dipyridamole, a 76.3% clinical improvement was recorded (mean increases of 11.2 ml/min. and 11.4 ml/min. of the cerebral hemispheric flows), 15.8% of cases stabilized (mean increases of 1.7 ml/min. and 1.2 ml/min.) and 7.9% failures (mean decreases of 10.4 ml/min. and 14.3 ml/min.) of these same flows. The cerebrography with xenon 133 inhaled as well as the platelet tests used, constitute unfailing means of diagnosing and monitoring the clinical development.
Get full access to this article
View all access options for this article.
References
1.
Cooper BS, Rice DP: The economic cost of illness revisited. Social Security Bulletin1976.
2.
Wolf PA: HTA as a risk factor for stroke. In: Cerebral vascular diseases-Winter conference. Ed. by Whisnant JP, Sandok BA.Furne and Stratton Inc, New York, 1974 , pp. 105-112.
3.
Barnett Hjm: The pathophysiology of transient cerebral ischemic attacks. Med Clin North Amer63: 4, 649, 1979.
4.
Harker LA, Ritchie JL: The role of platelets in acute vascular eventsCirculation62: (Suppl V) 13-18, 1980.
5.
Genton E., Barnett Hjm, Fields WS, et al: Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Stroke8: 1, 150-175, 1977.
6.
Charlier R.: Antianginal drugs. Springer-VerlagBerlin108-109, 1971.
7.
Solvay H., Kahn M.: Considérations à propos de la rétention plaquettaire sur billes de verre chez le patient athéromateux. Evaluation du rapport dose/réponse au dipyridamole. Acta Therapeutica7: 275-282, 1981.
8.
Solvay H., Van Schepdael J: Evaluation clinique et biologique du traitement à long terme par le dipyridamole de 190 patients athéromateux. Ars Medici36: 8, 795-805, 1981.
9.
Jorgensen KA , Dyerberg J., Stoffersen E.: PGI2 and the effect of phosphodiesterase inhibitors on platelet aggregation. Pharmacol Res Communic11: 7, 605, 1979.
